2024 UK Hepatitis A, B, C, D, E Diagnostics Market: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and NAT Tests, Technology and Instrumentation Review, Opportunities for Suppliers

August 2024 | - | ID: 2CBD6CA5D6D2EN
Venture Planning Group

Abstracts

The report presents a detailed analysis of the Hepatitis diagnostics market in the UK.The report is available by section, and can be customized to specific information needs and budget.Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets:%li%Hospitals %li%Commercial/Private Labs%li%Blood Banks%li%Public Health LabsIn addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests.Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.Contains 241 pages and 14 tables

Contents

I. Introduction
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized
Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Overview of Major Tests,
Technologies, and Instrumentation
A. Major Infectious Disease Tests

1. AIDS: HIV/HIV-1/2/COMBO, HIVAG/HIV NAT,

Western Blot, HTLV-I/II

2. ADENOVIRUS

3. AEROMONAS

4. ANTHRAX/BACILLUS ANTHRACIS

5. ARBOVIRUSES

6. BABESIOSIS

7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA)

and Other Bartonella (Rochalimaea)

8. BLASTOCYSTIS HOMINIS

9. BRUCELLA

10. CAMPYLOBACTER

11. CANDIDA

Table of Contents (continued)

12. CHAGAS DISEASE

13. CHANCROID

14. CHLAMYDIA

15. CLOSTRIDIUM DIFFICILE

16. CORONAVIRUSES

17. COXSACKIEVIRUSES

18. CREUTZFELDT-JAKOB’S DISEASE

19. CRYPTOSPORIDIUM PARVUM

20. CYCLOSPORA CAYETANENSIS

21. CYTOMEGALOVIRUS

22. EBOLA VIRUS

23. E. COLI

24. ECHOVIRUS

25. ENCEPHALITIS

26. ENTEROVIRUSES

27. EPSTEIN-BARR VIRUS

28. GIARDIA LAMBLIA

29. GONORRHEA

30. GRANULOMA INGUINALE

31. HANTAVIRUS

32. HELICOBACTER PYLORI

33. HEPATITIS: HAV NAT, HBV NAT, HBS AG, HCV, HCV NAT,

Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag,
HBe Ag, ALT/SGPT

34. HERPES SIMPLEX VIRUS

35. HUMAN HERPES VIRUS-6 (HHV-6)

36. INFLUENZA VIRUSES

37. LEGIONELLA

38. LYME DISEASE

39. LYMPHOGRANULOMA VENEREUM (LGV)

40. MALARIA

41. MEASLES (RUBEOLA)

42. MENINGITIS

43. MICROSPORIDIUM

44. MONONUCLEOSIS

45. MUMPS

46. MYCOPLASMA

47. PAPILLOMAVIRUSES

48. PARVOVIRUS B19

49. PNEUMONIA

50. POLYOMAVIRUSES

51. PSEUDOMONAS AERUGINOSA

52. RABIES

53. RESPIRATORY SYNCYTIAL VIRUS (RSV)

54. RHINOVIRUSES

55. ROTAVIRUS